Setting Non-profit psychiatric hospital. The economic analysis was carried out in the USA.

Similar documents
Prenatal purified protein derivative skin testing in a teaching clinic with a large Hispanic population Medchill M T

Study population Patients in the UK, with moderate and severe depression, and within the age range 18 to 93 years.

A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis Das A

Setting The setting of the study was tertiary care (teaching hospitals). The study was conducted in Hong Kong.

The DiSC assay: a cost-effective guide to treatment for chronic lymphocytic leukemia? Mason J M, Drummond M F, Bosanquet A G, Sheldon T A

Screening for malignant melanoma: a cost-effectiveness analysis Freedberg K A, Geller A C, Miller D R, Lew R A, Koh H K

Setting The setting was secondary care. The economic study was carried out in the UK.

Setting The setting was institutional and tertiary care in London, Essex and Hertfordshire in the UK.

Setting The study setting was hospital. The economic analysis was carried out in California, USA.

A randomized crossover study of silver-coated urinary catheters in hospitalized patients Karchmer T B, Giannetta E T, Muto C A, Strain B A, Farr B M

Economic analysis of initial HIV treatment: efavirenz- versus indinavir-containing triple therapy Caro J J, O'Brien J A, Miglaccio-Walle K, Raggio G

Cost-effectiveness of in vitro fertilisation and embryo transfer Mol B W, Bonsel G J, Collins J A, Wiegerinck M A, van der Veen F, Bossuyt P M

Type of intervention Treatment. Economic study type Cost-effectiveness analysis.

Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany Schadlich P K, Brecht J G

Source of effectiveness data The effectiveness data were derived from a review of completed studies and authors' assumptions.

Physician specialty and the outcomes and cost of admissions for end-stage liver disease Ko C W, Kelley K, Meyer K E

Health technology Lower-extremity amputation prevention strategies among individuals with diabetes.

Source of effectiveness data The evidence for final outcomes was derived from a review of the literature and a single survey study.

Clinical and financial analyses of laparoscopically assisted vaginal hysterectomy versus abdominal hysterectomy Hidlebaugh D, O'Mara P, Conboy E

Setting Community and hospital. The economic analysis was conducted in Ann Arbor, Michigan, USA.

Setting The setting was the community. The economic study was carried out in the USA.

Cost-effectiveness of gastric bypass for severe obesity Craig B M, Tseng D S

Cost-effectiveness of double-contrast barium enema in screening for colorectal cancer Glick S, Wagner J L, Johnson C D

Health technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study:

Type of intervention Treatment and secondary prevention. Economic study type Cost-effectiveness analysis.

Health technology The use of gonadotrophin-releasing hormone agonists (GnRHa) in women with uterine fibroids, undergoing hysterectomy or myomectomy.

Determining the cost-effectiveness of mass screening for cervical cancer using common analytic models Sato S, Matunaga G, Tsuji I, Yajima A, Sasaki H

Setting The setting was an outpatients department. The economic study was carried out in the UK.

Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China Ding D, Kilgore P E, Clemens J D, Liu W, Xu Z Y

Link between effectiveness and cost data Costing was conducted prospectively on the same patient sample as that used in the effectiveness analysis.

Clozapine in community practice: a 3-year follow-up study in the Australian Capital Territory Drew L R, Hodgson D M, Griffiths K M

Alternative management strategies for patients with suspected peptic ulcer disease Fendrick M A, Chernew M E, Hirth R A, Bloom B S

Cost-utility of initial medical management for Crohn's disease perianal fistulae Arseneau K O, Cohn S M, Cominelli F, Connors A F

Study population Male and female patients with bipolar I disorders who had been hospitalised for acute mania.

Comparison of safety and cost of percutaneous versus surgical tracheostomy Bowen C P R, Whitney L R, Truwit J D, Durbin C G, Moore M M

Health technology Using transcutaneous electrical nerve stimulation (TENS) in the pain management of chronic pain patients (CPPs).

Health technology Management, by cardiologists or generalists, of patients with congestive heart failure.

Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia Pokorn M, Kopac S, Neubauer D, Cizman M

Setting The setting was a hospital and the community. The economic analysis was carried out in the USA.

Setting The setting was primary care. The economic study was conducted in the UK.

The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women Haddix A C, Hillis S D, Kassler W J

The cost-effectiveness of omega-3 supplements for prevention of secondary coronary events Schmier J K, Rachman N J, Halpern M T

A cost-benefit analysis of an advocacy project to fluoridate toothpastes in Nepal Yee R, McDonald N, Walker D

Tuberculosis prevention in methadone maintenance clinics: effectiveness and costeffectiveness

Laparoscopy as the primary modality for the treatment of women with endometrial carcinoma Eltabbakh G H, Shamonki M I, Moody J M, Garafano L L

Helicobacter pylori-associated ulcer bleeding: should we test for eradication after treatment Pohl H, Finlayson S R, Sonnenberg A, Robertson D J

Impact of a critical pathway on inpatient management of diabetic ketoacidosis Ilag L L, Kronick S, Ernst R D, Grondin L, Alaniz C, Liu L, Herman W H

Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids Beinfeld M T, Bosch J L, Isaacson K B, Gazelle G S

A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis Choi H K, Seeger J D, Kuntz K M

Cost-effectiveness of hydroxyurea in sickle cell anemia Moore R D, Charache S, Terrin M L, Barton F B, Ballas S K

Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis Kantor J, Margolis D J

A cost-utility analysis of abdominal hysterectomy versus transcervical endometrial resection for the surgical treatment of menorrhagia Sculpher M

Is hospitalization after TIA cost-effective on the basis of treatment with tpa? Nguyen Huynh M N, Johnston S C

Setting The study setting was hospital. The economic analysis was carried out in Canada.

Improved antimicrobial interventions have benefits Barenfanger J, Short M A, Groesch A A

An economic evaluation of lung transplantation Anyanwu A C, McGuire A, Rogers C A, Murday A J

Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis.

Study population Pregnant HIV-infected women living in rural areas in resource-poor settings.

Source of effectiveness data The estimate for final outcomes was based on a synthesis of completed studies.

Setting The setting was secondary care. The economic study was carried out in Switzerland.

Cost-effectiveness considerations in the treatment of essential thrombocythemia Golub R, Adams J, Dave S, Bennett C L

Cost-effectiveness of the AMOArray multifocal intraocular lens in cataract surgery Orme M E, Paine A C, Teale C W, Kennedy L M

Cost-effectiveness of a preventive counseling and support package for postnatal depression Petrou S, Cooper P, Murray L, Davidson L L

Health technology Serological testing and endoscopy with biopsy for suspected peptic ulcer disease.

Source of effectiveness data Effectiveness data were derived from a single study combined with a review of previously completed studies.

Type of intervention Treatment. Economic study type Cost-effectiveness analysis.

Setting The setting was the community. The economic study was conducted in Yokohama city, Japan.

Treatment of Guillain-Barre syndrome: a cost-effectiveness analysis Nagpal S, Benstead T, Shumak K, Rock G, Brown M, Anderson D R

Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis Wingard J R, Wood C A, Sullivan E, Berger M L, Gerth W C, Mansley E C

Setting The setting was outpatient clinics. The economic analysis was conducted in Boston, USA.

Setting The setting was primary care. The economic study was carried out in the USA.

Buprenorphine versus methadone maintenance: a cost-effectiveness analysis Doran C M, Shanahan M, Mattick R P, Ali R, White J, Bell J

Setting Hospital. The study was carried out at Duke University Medical Center, Durham, North Carolina, USA.

Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Steinmetz K O, Volmer T, Trautmann M, Kielhorn A

Setting The setting was a hospital. The economic study was carried out in the USA.

Cost-effectiveness of pediatric heart transplantation Dayton J D, Kanter K R, Vincent R N, Mahle W T

Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis Provenzale D, Wong J B, Onken J E, Lipscomb J

Health technology The use of simvastatin to reduce low-density lipoprotein (LDL) cholesterol levels.

Using economics alongside medical audit: a case study of the management of endometriosis Bodner C, Vale L, Ratcliffe J, Farrar S

Cost-utility analysis of tympanomastoidectomy for adults with chronic suppurative otitis media Wang P C, Jang C H, Shu Y H, Tai C J, Chu K T

Cost-effectiveness of case management in substance abuse treatment Saleh S S, Vaughn T, Levey S, Fuortes L, Uden-Holmen T, Hall J A

Cost-effectiveness of a community-level HIV risk reduction intervention Pinkerton S D, Holtgrave D R, DiFranceisco W J, Stevenson L Y, Kelly J A

Pamidronate in prevention of bone complications in metastatic breast cancer: a costeffectiveness

Laparoscopic retropubic urethropexy Hannah S L, Chin A

Laparoscopic gastric bypass results in decreased prescription medication costs within 6 months Gould J C, Garren M J, Starling J R

Type of intervention Treatment. Economic study type Cost-effectiveness analysis.

Outcomes assessed in the review The review assessed adverse events, probability of discontinuation, toxicity, impotence, and survival.

Setting The study setting was hospital. The economic analysis appears to have been carried out in the USA.

Type of intervention Treatment. Economic study type Cost-effectiveness analysis.

Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers Scheid D C, Hamm R M, Stevens K W

Setting The setting was hospital and the economic analysis was carried out in the Netherlands.

The cost-effectiveness of anorexia nervosa treatment Crow S J, Nyman J A

Study population The study population comprised adult patients receiving UFH therapy for a broad range of conditions.

had non-continuous enrolment in Medicare Part A or Part B during the year following initial admission;

Setting The setting was a hospital. The economic study was conducted in the USA.

Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis

Type of intervention Screening and treatment. Economic study type Cost-utility analysis.

Transcription:

Inpatient alcohol treatment in a private healthcare setting: which patients benefit and at what cost? Pettinati H M, Meyers K, Evans B D, Ruetsch C R, Kaplan F N, Jensen J M, Hadley T R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Inpatient treatment of subjects with alcohol dependence. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Subjects with a Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R) diagnosis of alcohol dependence who were not dependent on any other substance, as confirmed by the Structured Clinical Interview for DSM-III-R (SCID). Patients were excluded if they were in severe withdrawal, had serious medical problems, or were courtmandated. Setting Non-profit psychiatric hospital. The economic analysis was carried out in the USA. Dates to which data relate Effectiveness and resource use data corresponded to patients admitted to the study institution between 1988 and 1992. The price year appears not to have been reported. Source of effectiveness data The evidence for the final outcomes was based on a single study. Link between effectiveness and cost data Costing was reported to have been conducted based on both the intention-to-treat principle (which was not reported in the paper) and treatment completers only (regarding those who successfully completed the two programmes). The costing appears to have been performed prospectively. Study sample Power calculations were not used to determine the sample size. The study sample consisted of 173 subjects who were clinically referred to either the inpatient group (n=93) with a mean (SD) age of 37.1 (10.8) years or to the outpatient group (n=80) with a mean (SD) age of 38.9 (10.1) years. The study sample was one of three different diagnostic subgroups (total n=305; 185 in the inpatient group and 120 in the outpatient group) who had participated in the parent Page: 1 / 5

study of the cost-effectiveness of inpatient versus outpatient addiction services. There were no differential study refusal rates by inpatients compared to outpatients. Study design This was a prospective cohort study, carried out in a single centre. Drinking status was evaluated during treatment, and at 3, 6, and 12 months after treatment. Regarding the loss to follow-up rate, it was reported that, of the 132 treatment responders, 75% had a follow-up status for the 12-month analysis, resulting in 99 subjects being evaluated (it was also reported that the outpatient group had a large attrition rate; however, the details of drop out rates were published elsewhere). Patients were clinically referred (not "assigned") to inpatient or outpatient treatment by clinically-trained programme staff who had access to the patient's medical and psychiatric history and current status via a psychosocial and diagnostic interview conducted by a psychiatrist. Analysis of effectiveness The principle used in the analysis of effectiveness appears to have been both intention-to-treat and treatment completers only. The primary health outcome measure was drinking status (the rates of significant drinking in the post-treatment period). Significant drinking was defined as: (1) reported consumption of 3 or more alcoholic drinks in a sitting, (2) admission to an inpatient or detoxification centre, and/or (3) incarceration due to alcohol-related behaviours. An abbreviated version of the Timeline Followback (TLFB) was used to document a return to significant drinking during and after treatment discontinuation to record the number of drinking days. Psychiatric symptoms and alcoholrelated consequences were assessed at treatment entry with two standardised, self-report measures. The Symptom Checklist-90-Revisited (SCL-90-R) was used to assess psychiatric symptoms. The Michigan Alcohol Screening Test- Revisited (MAST-R) was used to measure the number of lifetime alcohol-related consequences. A survival (no significant drinking) analysis was conducted to evaluate whether there were differences between the two study groups in the rate of return to significant drinking following treatment up to 12 months after treatment. A hierarchical logistic regression analysis was used to assess significant drinking rates for inpatients compared to outpatient responders at all three follow-up points while covarying subjects for the number of lifetime drinking consequences they reported at pretreatment. The study groups were comparable in terms of baseline demographic (except for socio-economic status, which was lower for the inpatients versus outpatients) and clinical characteristics (in terms of the mean global SCL-90-R and MAST-R scores). Effectiveness results The effectiveness results were as follows: There were significantly more inpatients than outpatients who attended most of the treatment visits and who were not drinking by the end of treatment (84, or 90% of inpatients versus 48, or 60% of outpatients, (p<0.01)). Comparison of the rates of significant drinking in the post-treatment period between inpatient and outpatient responders using survival analyses showed that there were no significant differences between the two curves. The measures targeted for the matching analyses, SCL-90-R and MAST-R, were positively correlated with one another (Pearson's r=0.33; p<0.05). However, in the logistic regression analysis, only the MAST-R scores (and not the SCL-90-R scores) related to significant drinking, most notably at the first post-treatment follow-up at 3 months. The study found that subjects who had high MAST-R ratings at treatment entry had reduced rates of significant drinking in the three month period after successfully completing inpatient compared to outpatient treatment (p<0.05; odds ratio: 2.41). Page: 2 / 5

There were no significant interactions between treatment setting and outcome based on the MAST-R scores at the 6-month follow-up (p>0.35; odds ratio: 1.48), nor at the 12-month follow-up (p>0.25; odds ratio: 1.66). Clinical conclusions Patients with multiple drinking-related consequences were less likely to return to significant drinking in the first 3 months after treatment if they had attended inpatient rather than outpatient treatment. Thus, inpatient treatment appeared to have some advantage over outpatient treatment in the early recovery period for patients with multiple drinking-related consequences. Measure of benefits used in the economic analysis As mentioned by the authors, the health summary benefit measure was the probability of returning to significant drinking, given the subject's psychiatric severity and/or number of drinking consequences at treatment entry. This probability was obtained for each subject directly from the logistic regression that tested the interaction between treatment setting and MAST-R scores in predicting outcomes. Direct costs Costs were not discounted due to the short time frame of the cost analysis. Some quantities were reported separately from the costs. Cost items were not reported separately. Cost analysis covered the direct costs of delivering the treatment services and transportation. The perspective adopted in the cost analysis appears to have been that of the private payer. A modified version of the Treatment Services Review (TSR) was used to record the total number of treatment service hours attended during the intensive treatment programme each week via interviews with the subject. A weighted cost-to-charge ratio was applied to the billing charges for services to adjust for geographic- or institutionspecific charges. The cost analysis was based on both intention-to-treat (which was not reported in the paper) and treatment completers only. The price year appears not to have been reported. Statistical analysis of costs Student's t test was used to compare the study groups in terms of costs. Indirect Costs It was reported that wage loss was included in the cost calculation, but no further information was provided. Currency US dollars ($). Sensitivity analysis Not conducted. Estimated benefits used in the economic analysis The logistic regression analysis of probability of significant drinking at 3 months after attending an inpatient or outpatient programme for 124 treatment programme responders (94% followed) resulted in the following parameter estimates: Intercept, parameter estimate: -0.7879; odds ratio: 0.455; Treatment Programme, parameter estimate: -1.1077; odds ratio: 0.330; MAST-R, parameter estimate: -0.2457; odds ratio: 0.782; Page: 3 / 5

MAST-R x Tx Programme, parameter estimate: 0.8810; odds ratio: 2.413; p<0.05; Full model, p<0.01; concordance = 64.5%. The analysis showed that subjects with higher MAST-R scores had a greater probability of returning to significant drinking in the first 3 months post-treatment if they had been in the outpatient rather than the inpatient programme. Cost results For treatment responders, the average (SD) cost of successfully completing inpatient treatment was $9,014 ($2,986) versus $1,420 ($619), (p< 0.01); a ratio of 6.5:1. Synthesis of costs and benefits The cost-effectiveness ratio was calculated by dividing treatment costs by the probability of returning to significant drinking. For treatment responders, the inpatient:outpatient cost-effectiveness ratio was calculated for the 3-month follow-up at 4.5:1, at the 6-month follow-up at 5.3:1, and at the 12-month follow-up at 5.6:1. Authors' conclusions Identifying better patient outcomes in early recovery with inpatients rather than outpatient treatment makes this one of the "rare" research reports that found something favourable about inpatient over outpatient treatment, even if only in the early stages of recovery. CRD COMMENTARY - Selection of comparators The outpatient programme, as a widely acceptable method of delivering services in the context in question, was regarded as the comparator. You, as a database user, should consider which health technology is used widely in your own setting. Validity of estimate of measure of effectiveness The internal validity of the effectiveness results can not be fully guaranteed due to the non-randomised nature of the study design (it was reported that a non-randomised design was used to preclude the possibility of excluding more severely-impaired patients) and the fact that no power calculations were performed. Furthermore, it was noted that the poorer results for the outpatient group in the first three months may have resulted from improper clinical referral of some patients to an outpatient rather than a more intensive inpatient setting. The study groups were comparable in terms of baseline demographic and clinical characteristics, except for socio-economic status, which was lower for the inpatient group. The study sample appears to have been representative of the study population. Validity of estimate of measure of benefit Estimation of benefits was obtained directly from the effectiveness analysis using the logistic regression analysis. This choice of estimate was justified. Validity of estimate of costs The validity of the cost results was enhanced by the following positive features of the cost analysis: some quantities were reported separately from the costs; the perspective adopted in the cost analysis was reported; a cost-to-charge ratio was used to adjust for local or institution specific factors; the effects of alternative procedures on indirect costs appear to have been addressed; and statistical analyses were performed on some resource consumption and cost data. However, the validity of the cost results may have been weakened by the following characteristics: adequate details of methods of cost estimation were not given, for example it was not reported how the transportation and wage loss costs were calculated; the price year was not specified and it is not clear whether the cost data were adjusted for inflation; cost results may not be generalisable outside the study setting. Page: 4 / 5

Powered by TCPDF (www.tcpdf.org) Other issues The study results may need to be treated with a good degree of caution given the limitations of the study design described above. The issue of generalisability to other settings or countries was addressed. The authors noted that the study group of middle-to-upper socio-economic status who received treatment at a non-profit, private-pay facility limits the generalisability of the results in this study. Appropriate comparisons were made with other studies. The question of whether the study sample was representative of the study population was addressed in the authors' general comments. Implications of the study The authors hope that the study results will stimulate examination of causal factors that may account for the "continued" improvement seen for selected inpatients. In addition, it would be important to continue investigating optimal referral criteria for inpatient or other intensive treatment programmes so that "high-problem" patients will not be forced to first fail outpatient treatment before they can be admitted to inpatient treatment (the most expensive alcohol treatment course). Source of funding Supported by the National Institute on Alcohol Abuse and Alcoholism, Grant AA07831. Bibliographic details Pettinati H M, Meyers K, Evans B D, Ruetsch C R, Kaplan F N, Jensen J M, Hadley T R. Inpatient alcohol treatment in a private healthcare setting: which patients benefit and at what cost? American Journal on Addictions 1999; 8(3): 220-233 PubMedID 10506903 Other publications of related interest Pettinati HM, Belden PP, Evans BD, Ruetsch CR, Meyers K, Jensen JM. The natural history of outpatient alcohol and drug abuse treatment in a private healthcare setting. Alcoholism: Clinical and Experimental Research 1996;20:847-852. Indexing Status Subject indexing assigned by NLM MeSH Adult; Alcoholism /economics /therapy; Ambulatory Care /economics; Cost-Benefit Analysis; Female; Health Care Costs /statistics & numerical data; Hospitalization /economics; Humans; Male; Middle Aged; Outcome Assessment (Health Care); Recurrence AccessionNumber 22000006012 Date bibliographic record published 31/03/2001 Date abstract record published 31/03/2001 Page: 5 / 5